Stock 1167 JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Jacobio Pharmaceuticals Group Co., Ltd. Share Price

Equities

1167

KYG4987A1094

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:10 21/05/2024 pm IST 		5-day change 1st Jan Change
1.88 HKD -4.08% Intraday chart for Jacobio Pharmaceuticals Group Co., Ltd. +3.30% -48.07%
13/05 Jacobio Pharmaceuticals Reports Approval for Phase 3 Trial for Combination Therapy Between Glecirasib and Cetuximab MT
10/05 Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * - Sales 2025 * 60.31M 8.34M 65.04M 694M Capitalization 1.44B 199M 1.55B 16.57B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * 462M 63.92M 499M 5.32B Net cash position 2025 * 703M 97.13M 758M 8.09B EV / Sales 2025 * 12.2 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 301
Yield 2024 *
-
Yield 2025 *
-
Free-Float 55.92%
More Fundamentals * Assessed data

Chart Jacobio Pharmaceuticals Group Co., Ltd.

Dynamic Chart

Latest news about Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Reports Approval for Phase 3 Trial for Combination Therapy Between Glecirasib and Cetuximab MT
Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer CI
Jacobio Pharmaceuticals Submits Cancer Treatment New Drug Application to Chinese Drug Regulator; Shares Surge 22% MT
Jacobio Pharma Announces Its KRAS G12C Inhibitor Reached the Primary Endpoint CI
Jacobio Pharmaceuticals Plans Auditor Change MT
Jacobio to Share Clinical Data of Anti-Tumor Drugs at US Convention MT
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting CI
Jacobio Pharmaceuticals Narrows 2023 Loss on Lower R&D Expenses MT
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jacobio Pharmaceuticals Gets US FDA Clearance for Phase 1/2 Clinical Trial for Anti-Tumor Drug; Shares Surge 16% MT
Jacobio Pharmaceuticals Group Co., Ltd. Receives US FDA Investigational New Drug Clearance for P53 Y220C Activator JAB-30300 CI
Hong Kong Stocks Fall as Chinese Central Bank Leaves Key Policy Rate on Hold; Jacobio Falls 11% Despite Drug Progress MT
China Approves Jacobio's Phase 3 Trial of Non-Small Cell Lung Cancer Drug; Shares Plummet 13% MT
Jacobio Pharma Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor CI
Jacobio Presents Clinical Data on Pancreatic Cancer Treatment at Oncology Meet; Shares Fall 7% MT
More news

Analyst Recommendations on Jacobio Pharmaceuticals Group Co., Ltd.

Hong Kong Stocks Fall as Chinese Central Bank Leaves Key Policy Rate on Hold; Jacobio Falls 11% Despite Drug Progress MT
More recommendations

Press releases Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharma Announces 2022 Annual Results PR
Jacobio Pharmaceuticals : VOLUNTARY ANNOUNCEMENT JACOBIO ANNOUNCES THE FIRST PATIENT DOSED IN CLINICAL TRIAL OF KRAS G12C JAB-21822 IN CHINA PU
Jacobio Pharmaceuticals : VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVES US FDA INVESTIGATIONAL NEW DRUG CLEARANCE FOR KRAS G12C INHIBITOR PU
Jacobio Pharmaceuticals : RESIGNATION OF PRESIDENT OF RESEARCH AND DEVELOPMENT AND APPOINTMENT OF CHIEF BIOLOGIST PU
Jacobio Pharmaceuticals : PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING PU
More press releases

Quotes and Performance

1 day-4.08%
1 week+3.30%
Current month+11.24%
1 month+28.77%
3 months-18.26%
6 months-56.38%
Current year-48.07%
More quotes

Highs and lows

1 week
1.78
Extreme 1.78
1.99
1 month
1.39
Extreme 1.39
2.52
Current year
1.38
Extreme 1.38
3.71
1 year
1.38
Extreme 1.38
7.06
3 years
1.38
Extreme 1.38
24.60
5 years
1.38
Extreme 1.38
25.35
10 years
1.38
Extreme 1.38
25.35
More quotes

Managers and Directors - Jacobio Pharmaceuticals Group Co., Ltd.

Managers TitleAgeSince
Yin Xin Wang CEO
 Chief Executive Officer 59 01/18/01
Hai Jun Wang CTO
 Chief Tech/Sci/R&D Officer - -
Andrea Wang-Gillam CTO
 Chief Tech/Sci/R&D Officer 54 16/20/16
Members of the board TitleAgeSince
Rui Lin Song BRD
 Director/Board Member 61 20/20/20
Xiaojie Wang ADM
 Chief Administrative Officer 60 31/18/31
Yun Yan Hu BRD
 Director/Board Member 61 31/18/31
More insiders

ETFs positioned on Jacobio Pharmaceuticals Group Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
0.85% 4 M€ -27.92%
More ETFs positioned on Jacobio Pharmaceuticals Group Co., Ltd.

Quotes

Date Price Change Volume
21/24/21 1.88 -4.08% 1 035 600
20/24/20 1.96 +4.81% 1,489,200
17/24/17 1.87 +1.08% 1,096,800
16/24/16 1.85 +1.65% 972,600
14/24/14 1.82 +1.11% 1,405,500

Delayed Quote Hong Kong S.E., May 21, 2024 at 01:38 pm IST

More quotes

Company Profile

Jacobio Pharmaceuticals Group Co Ltd is a China-based investment holding company mainly engaged in the research and development of new drugs at the clinical stage. The Company is primarily responsible for the independent discovery and development of innovative tumor therapies. The Company's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The Company mainly conducts business within the domestic market.
Sector
Biotechnology & Medical Research
Calendar
28/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.818 CNY
Average target price
3.954 CNY
Spread / Average Target
+117.46%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
JACOBIO PHARMACEUTICALS GROUP CO., LTD. Stock Jacobio Pharmaceuticals Group Co., Ltd.
-48.07% 199M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.58% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.41% 107B
ARGENX SE Stock argenx SE
-3.52% 21.6B
BIONTECH SE Stock BioNTech SE
-12.38% 22.31B
GENMAB A/S Stock Genmab A/S
-6.50% 19.19B
BEIGENE, LTD. Stock BeiGene, Ltd.
-3.35% 18.23B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.57% 17.62B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.51% 14.26B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.67% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 1167 Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW